Tetraphase Pharmaceuticals Provides Update on Clinical Progress of Phase 3 …

Published March 21, 2014

Tetraphase Pharmaceuticals Provides Update on Clinical Progress of Phase 3 …
[rewrite]WATERTOWN, MA, USAI March 20, 2014 I Tetraphase Pharmaceuticals, Inc. (TTPH) today provided a clinical update on its lead antibiotic candidate, eravacycline, and its Phase 3 global clinical program IGNITE (Investigating Gram-negative Infections Treated …[/rewrite]
Read more on PipelineReview.com (press release)

GlaxoSmithKline's cancer vaccine MAGE-A3 suffers its second PhIII flop
[rewrite]Another top prospect for the Duchenne muscular dystrophy therapy drisapersen is being handed back to Prosensa ($ RNA) after that drug failed a late-stage program as well last year. The failure … "We are disappointed that the trial did not demonstrate …[/rewrite]
Read more on FierceBiotech

Acetylon Pharmaceuticals Celebrates Headquarters Expansion in Boston's …
[rewrite]“Acetylon is well-positioned to make a positive impact on the treatment of cancer in the coming years and further the standing of Boston as a global leader in biotech and the life sciences” commented Mayor Marty Walsh. “We are pleased that Acetylon …[/rewrite]
Read more on PharmiWeb.com (press release)

Related Drug Treatment Programs In Massachusetts Information…